4/23/2013

InspireMD has secured net proceeds of $22.6 million in a public offering of company shares. The Israeli device firm will use part of the funding to seek FDA approval of its MGuard carotid and coronary stents, which are used to prevent the risk of embolism in patients who have undergone stenting procedures.

Related Summaries